QALYs or quackery? The quagmire of quantifying the cost of breathing

Journal of Thoracic and Cardiovascular Surgery

Volumn 123, Issue 3, 2002, Pages 406-408

  Egan, Thomas M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; EDITORIAL; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LUNG DISEASE; LUNG TRANSPLANTATION; ORGAN DONOR; PALLIATIVE THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036521129     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2002.121526     Document Type: Article

References (17)

1. Williams A. The role of health economics in clinical decision-making: is it ethical? Respir Med. 1991;85 Suppl B:3-5.
2. Anyanwu AC, McGuire A, Rogers CA, Murday AJ. An economic evaluation of lung transplantation. J Thorac Cardiovasc Surg. 2002;123:411-20.
3. Anyanwu AC, McGuire A, Rogers CA, Murday AJ. Assessment of quality of life in lung transplantation using a simple generic tool. Thorax. 2001;56:218-22.
4. Burker EJ, Carels RA, Thompson LF, Rodgers L, Egan T. Quality of life in patients awaiting lung transplant: cystic fibrosis versus other end-stage lung diseases. Pediatr Pulmonol. 2000;30:453-60.
5. Brown GC, Sharma S, Brown MM, Garrett S. Evidence-based medicine and cost-effectiveness. J Health Care Finance. 1999;26:14-23.
6. Nord E, Pinto JL, Richardson J, Menzel P, Ubel P. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ. 1999;8:25-39.
7. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet. 1998;351:24-7.
8. Robinson R. Cost-utility analysis. BMJ. 1993;307:859-62.
9. Petrou S, Renton A. The QALY: a guide for the public health physician. Public Health. 1993;107:327-36.
10. Fryback DG, Lawrence WF. Dollars may not buy as many QALYs as we think: a problem with definig quality-of-life adjustments. Med Decis Making. 1997;17:276-84.
11. Nord E. The relevance of health state after treatment in prioritising between different patients. J Med Ethics. 1993;19:37-42.
12. Ramsey SD, Patrick DL, Albert RK, Larson EB, Wood DE, Raghu G. The cost-effectiveness of lung transplantation: a pilot study. University of Washington Medical Center Lung Transplant Study Group. Chest 1995;108:1594-601.
13. van Enckovert PJ, TenVergert EM, Bonsel GJ, Geertsma A, van-der BW, de BW et al. Technology assessment of the Dutch Lung Transplantation Program. Int J Technol Assess Health Care. 1998;14:344-56.
14. Hadorn DC. Setting health care priorities in Oregon: cost effectivness meets the rule of rescue. JAMA. 1991;265:2218-25.
15. Jonsen AR. Bentham in a box - technology assessment and health care allocation. Law Med Health Care. 1986;14:172-4.
16. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20:332-42.
17. Orenstein DM, Kaplan RM. Measuring the quality of well-being in cystic fibrosis and lung transplantation: the importance of the area under the curve. Chest. 1991;100:1016-8.